Factor VIII

Results: 143



#Item
61RECOMBINATE Antihemophilic Factor (Recombinant) Lyophilized Powder for Reconstitution for injection Reconstitute with 5 mL of Sterile Water for Injection using double-ended needles

RECOMBINATE Antihemophilic Factor (Recombinant) Lyophilized Powder for Reconstitution for injection Reconstitute with 5 mL of Sterile Water for Injection using double-ended needles

Add to Reading List

Source URL: www.fda.gov

Language: English
62HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Novoeight safely and effectively. See full prescribing information for Novoeight.  -------------------------------CO

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Novoeight safely and effectively. See full prescribing information for Novoeight. -------------------------------CO

Add to Reading List

Source URL: www.fda.gov

Language: English
63Hemophilia Enhanced Specialty Discount Products Therapeutic Group  Label Name

Hemophilia Enhanced Specialty Discount Products Therapeutic Group Label Name

Add to Reading List

Source URL: www.ncdhhs.gov

Language: English - Date: 2014-10-08 15:19:43
64SCIENTIFIC PRIZES MCKINSEY & COMPANY 2014 OCTOBER 9, 2014  Pour tout renseignement:

SCIENTIFIC PRIZES MCKINSEY & COMPANY 2014 OCTOBER 9, 2014 Pour tout renseignement:

Add to Reading List

Source URL: www2.frs-fnrs.be

Language: English - Date: 2014-12-02 04:14:29
65DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH RECOMBINANT DNA ADVISORY COMMITTEE MINUTES OF MEETING March 8-10, 2000 CONTENTS

DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH RECOMBINANT DNA ADVISORY COMMITTEE MINUTES OF MEETING March 8-10, 2000 CONTENTS

Add to Reading List

Source URL: osp.od.nih.gov

Language: English - Date: 2014-01-14 14:18:46
66A Study of Prospective Surveillance for Inhibitors among Persons with Haemophilia in the United States J. Michael Soucie, 1 Connie H. Miller, 1 Fiona M. Kelly, 1 Amanda B. Payne, 1 Melissa Creary, 1 Paula L. Bockenstedt,

A Study of Prospective Surveillance for Inhibitors among Persons with Haemophilia in the United States J. Michael Soucie, 1 Connie H. Miller, 1 Fiona M. Kelly, 1 Amanda B. Payne, 1 Melissa Creary, 1 Paula L. Bockenstedt,

Add to Reading List

Source URL: www.hemophiliafed.org

Language: English - Date: 2014-05-23 16:11:58
67VARIANT CJD RISK ASSESSMENT AND COMMUNICATION PLAN FOR PLASMA DERIVED COAGULATION FACTOR VIII

VARIANT CJD RISK ASSESSMENT AND COMMUNICATION PLAN FOR PLASMA DERIVED COAGULATION FACTOR VIII

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2006-11-27 11:12:00
68Summary Basis for Regulatory Action-Wilate

Summary Basis for Regulatory Action-Wilate

Add to Reading List

Source URL: www.fda.gov

Language: English
69VIRUS TRANSMISSION ‘BY BLOOD PRODUCTS: \\ DETECTION OF INFEChOUS HEPATITIS A VIRUS IN FACTOR VIII CONCENTRATES BY EXPERIMENTAL INFECTION

VIRUS TRANSMISSION ‘BY BLOOD PRODUCTS: \\ DETECTION OF INFEChOUS HEPATITIS A VIRUS IN FACTOR VIII CONCENTRATES BY EXPERIMENTAL INFECTION

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2000-06-12 08:44:33
70TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE December 15, 2006 REFERENCES  Topic I: FDA’s risk assessment for potential exposure to vCJD in human plasma-

TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE December 15, 2006 REFERENCES Topic I: FDA’s risk assessment for potential exposure to vCJD in human plasma-

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2006-11-27 11:12:00